Biohaven Ltd
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
BHVN$15.23+5.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Operating expenses: | |||
| Research and development | $373,281 | $437,072 | $181,486 |
| General and administrative | 62,770 | 130,860 | 37,414 |
| Total operating expenses | 436,051 | 567,932 | 218,900 |
| Loss from operations | (436,051) | (567,932) | (218,900) |
| Other income (expense): | |||
| Gain from equity method investment | — | — | 5,261 |
| Other income (expense), net | 26,500 | (1,909) | 1,209 |
| Total other income (expense), net | 26,500 | (1,909) | 6,470 |
| Loss before (benefit) provision for income taxes | (409,551) | (569,841) | (212,430) |
| (Benefit) provision for income taxes | (1,383) | 438 | 1,366 |
| Net loss | $(408,168) | $(570,279) | $(213,796) |
| Net loss per share — basic and diluted | $(5.73) | $(12.75) | $(5.43) |
| Weighted average common shares outstanding—basic and diluted | 71,200,527 | 44,741,316 | 39,375,944 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.